{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:54:26Z","timestamp":1784166866169,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinthera.2021.11.015","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:32:30Z","timestamp":1642595550000},"page":"81-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Importance of Time Point\u2013Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses"],"prefix":"10.1016","volume":"44","author":[{"given":"Damon","family":"Willems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Pinedo-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Yehoshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mata","family":"Charokopou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.11.015_bib0001","unstructured":"Broken bones, broken lives: a roadmap to solve the fragility fracture crisis in Europe 2018 [Available from: https:\/\/www.iofbonehealth.org\/broken-bones-broken-lives."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"Sozen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0004","unstructured":"European Medicines Agency. Approval of the marketing authorisation for Evenity (romosozumab) 2019 [Available from: http:\/\/www.eemmo.gr\/DOCS\/2019\/EMA%20Approval%20marketing%20authorisation,%20evenity%20(romosozumab).pdf."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0006","unstructured":"European Medicines Agency. Evenity (romosozumab) Summary of Product Characteristics 2020 [cited 2020 20 April]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evenity-epar-product-information_en.pdf."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0007","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0009","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","article-title":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"129","author":"Hernandez","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/GME.0000000000001321","article-title":"Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China)","volume":"26","author":"Tan","year":"2019","journal-title":"Menopause (New York, NY)"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0013","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/GME.0000000000000466","article-title":"Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis","volume":"22","author":"Zhang","year":"2015","journal-title":"Menopause (New York, NY)."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"van Geel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0017","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00198-020-05765-7","article-title":"A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis","volume":"32","author":"Soreskog","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0019","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0021","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0023","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0024","unstructured":"UCB\/AMGEN. Primary Analysis Data ARCH (33 months) - Internal Analysis Document."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0026","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative Effects of Raloxifene and Alendronate on Fracture Outcomes in Postmenopausal Women With Low Bone Mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0027","series-title":"NICE Decision Support Unit Technical Support Documents. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in medicine"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0029","unstructured":"Sofia Dias NJW, Alex J Sutton, Deborah M Caldwell, Guobing Lu, AE Ades. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials 2014 [Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD4-Inconsistency.final_.15April2014.pdf."},{"key":"10.1016\/j.clinthera.2021.11.015_bib0030","series-title":"WinBUGS User Manual","year":"2003"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0031","series-title":"RStudio","year":"2018"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0032","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0038-1660790","article-title":"Osteoporosis: Current Concepts","volume":"6","author":"Akkawi","year":"2018","journal-title":"Joints"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0033","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0034","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","article-title":"Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial","volume":"25","author":"Grey","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0035","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J Clin Endocrinology Metab"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0036","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0037","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00223-020-00750-y","article-title":"Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis","volume":"107","author":"Okubo","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0038","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0039","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis","volume":"89","author":"Sanderson","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0041","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis","volume":"2","author":"Benjamin","year":"2016","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0042","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11005\/jbm.2017.24.1.37","article-title":"The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis","volume":"24","author":"Byun","year":"2017","journal-title":"J Bone Metab"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0043","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0044","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168691","article-title":"Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis","volume":"11","author":"Shi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0046","doi-asserted-by":"crossref","first-page":"e6970","DOI":"10.1097\/MD.0000000000006970","article-title":"Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0047","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11657-019-0569-2","article-title":"Imminent fracture risk assessments in the UK FLS setting: implications and challenges","volume":"14","author":"Pinedo-Villanueva","year":"2019","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0048","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","article-title":"Characteristics of recurrent fractures","volume":"29","author":"Kanis","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0049","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","article-title":"Romosozumab for the treatment of osteoporosis","volume":"4","author":"McClung","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.clinthera.2021.11.015_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2021.11.015_bib51","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The Effect of Teriparatide Compared with Risedronate on Reduction of Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:42Z","timestamp":1758963342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821004896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0149291821004896"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance of Time Point\u2013Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}